Veradermics (MANE) Operating Expenses (2025 - 2026)
Veradermics (MANE) posted Operating Expenses of $29.9 million for Q1 2026, up 131.22% on a QoQ basis from $12.9 million in Q1 2025, and up 131.22% year-over-year from $12.9 million in Q1 2025.
Veradermics (MANE) Operating Expenses (2025 - 2026) Analysis & Trends
Veradermics' Operating Expenses history runs 2 years deep, the most recent figure standing at $29.9 million for Q1 2026.
- Quarterly Operating Expenses rose 131.22% year-over-year to $29.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42.8 million (changed N/A YoY) and the FY2025 annual result came in at $72.3 million, up 170.17% from the prior year.
- Operating Expenses was $29.9 million for Q1 2026 at Veradermics, up from $12.9 million in the prior quarter.
- Across five years, Operating Expenses topped out at $29.9 million in Q1 2026 and bottomed at $12.9 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -28.01 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.10 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.78 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.85 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 32.68 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 2.89 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 445.22 Mn |
| 10 | Veradermics | 2.63 Bn | 2.63 Bn | - | 29.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29.86 Mn |
| Mar 31, 2025 | 12.92 Mn |